44
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Formulation optimization of scutellarin-loaded HP-β-CD/chitosan nanoparticles using response surface methodology with Box–Behnken design

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Graphical Abstract

          The scutellarin (SCU)-loaded HP-β-CD /chitosan (CS) nanoparticles (CD/CS-SCU-NPs) were prepared using ionic gelation method. Response surface design was used to optimize the formulation. The optimum formulation was tested in vitro.

          Abstract

          The aim of this paper is to investigate and optimize the preparation of scutellarin (SCU)-loaded HP-β-CD /chitosan (CS) nanoparticles (CD/CS-SCU-NPs). CD/CS-SCU-NPs were prepared by ionic cross-linking method and the process and formulation variables were optimized using response surface methodology (RSM) with a three-level, three factor Box–Behnken design (BBD). The independent variables were the added amounts of CS, sodium tripolyphosphate (TPP) and Pluronic F-68 during the preparation. Dependent variables (responses) were particle size and entrapment efficiency. Mathematical equations and respond surface plots were used to correlate independent and dependent variables. The preparation process and formulation variables were optimized to achieve minimum particle size and maximum entrapment efficiency by calculating the overall desirability value (OD). The optimized NP formulation was characterized for particle size, PDI, zeta potential, entrapment efficiency and in vitro drug release. According to the results, an optimized CD/CS-SCU-NP formulation was prepared. Results for particle size, PDI, zeta potential and entrapment efficiency were found to be around 200 nm, 0.5, 25 mV, and 70% respectively. For in vitro study, the release of SCU from the NPs exhibited a biphasic release and was in accordance with Higuchi equation. The optimized preparation was simple with the probability for industrialization. The combination use of RSM, BBD and overall desirability values could provide a promising application for incorporating CD into CS nanoparticles as drug delivery carrier and help develop lab-scale procedures.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Cyclodextrins in delivery systems: Applications

          Cyclodextrins (CDs) are a family of cyclic oligosaccharides with a hydrophilic outer surface and a lipophilic central cavity. CD molecules are relatively large with a number of hydrogen donors and acceptors and, thus in general, they do not permeate lipophilic membranes. In the pharmaceutical industry, CDs have mainly been used as complexing agents to increase aqueous solubility of poorly soluble drugs and to increase their bioavailability and stability. CDs are used in pharmaceutical applications for numerous purposes, including improving the bioavailability of drugs. Current CD-based therapeutics is described and possible future applications are discussed. CD-containing polymers are reviewed and their use in drug delivery is presented. Of specific interest is the use of CD-containing polymers to provide unique capabilities for the delivery of nucleic acids. Studies in both humans and animals have shown that CDs can be used to improve drug delivery from almost any type of drug formulation. Currently, there are approximately 30 different pharmaceutical products worldwide containing drug/CD complexes in the market.
            • Record: found
            • Abstract: found
            • Article: not found

            Nasal drug administration: potential for targeted central nervous system delivery.

            Nasal administration as a means of delivering therapeutic agents preferentially to the brain has gained significant recent interest. While some substrates appear to be delivered directly to the brain via this route, the mechanisms governing overall brain uptake and exposure remain unclear. Some substrates utilize the olfactory nerve tract and gain direct access to the brain, thus bypassing the blood-brain barrier (BBB). However, most agents of pharmacologic interest likely gain access to the brain via the olfactory epithelium, which represents a more direct route of uptake. While the traditional BBB is not present at the interface between nasal epithelium and brain, P-glycoprotein (and potentially other barrier transporters) is expressed at this interface. In addition, work in this laboratory has demonstrated that P-glycoprotein throughout the brain can be modulated with nasal administration of appropriate inhibitors. The potential for targeted central nervous system delivery via this route is discussed. (c) 2005 Wiley-Liss, Inc.
              • Record: found
              • Abstract: found
              • Article: not found

              Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis.

              Hu Yang (2010)
              Central nervous system (CNS) diseases represent the largest and fastest-growing area of unmet medical need. Nanotechnology plays a unique instrumental role in the revolutionary development of brain-specific drug delivery, imaging, and diagnosis. With the aid of nanoparticles of high specificity and multifunctionality, such as dendrimers and quantum dots, therapeutics, imaging agents, and diagnostic molecules can be delivered to the brain across the blood-brain barrier (BBB), enabling considerable progress in the understanding, diagnosis, and treatment of CNS diseases. Nanoparticles used in the CNS for drug delivery, imaging, and diagnosis are reviewed, as well as their administration routes, toxicity, and routes to cross the BBB. Future directions and major challenges are outlined.

                Author and article information

                Contributors
                Journal
                Asian J Pharm Sci
                Asian J Pharm Sci
                Asian Journal of Pharmaceutical Sciences
                Shenyang Pharmaceutical University
                1818-0876
                2221-285X
                21 April 2017
                July 2017
                21 April 2017
                : 12
                : 4
                : 378-385
                Affiliations
                National University of Singapore, 21 Kent Ridge Road, Singapore
                Author notes
                [* ]Corresponding author. National University of Singapore, 21 Kent Ridge Road, Singapore. Tel: +65 6516 2651; Fax: +65 6779 1554. phahocl@ 123456nus.edu.sg
                Article
                S1818-0876(17)30093-4
                10.1016/j.ajps.2017.04.003
                7032107
                32104349
                a8d78b30-80a7-47b6-a461-0b5123329388
                © 2017 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 23 February 2017
                : 27 March 2017
                : 3 April 2017
                Categories
                Original Research Article

                scutellarin,response surface methodology,box–behnken design,chitosan,hp-β-cd,nanoparticles

                Comments

                Comment on this article

                Related Documents Log